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A R T I C L E  I N F O A B S T R A C T
Congenital hyperinsulinism (CHI) is a rare genetic dis-
order characterized by inappropriate insulin secre-
tion and severe hypoglycaemia. There are two histo-
logical subtypes: diffuse and focal form. Diffuse form 
is most common in autosomal recessive mutations in 
ABCC8/KCNJ11 gene, while focal CHI is caused a pa-
ternally inherited mutation and a somatic maternal 
allele loss. 
Here we report a case of a term male infant present-
ed with severe hyperinsulinaemic hypoglycaemia. 
Gene panel testing was performed to give rapid ge-
netic diagnosis. We detected the c.4415-13G>A het-
erozygous mutation in the ABCC8 gene. Targeted ge-
netic testing of the parents proved the de novo origin 
of the mutation. The mutation has been previously 
described. The infant received octreotide treatment 
and is prepared for 18-fluoro-dopa PET-CT examina-
tion in order to localize the lesion. 
Rapid genetic testing might be crucial in the clinical 
management strategy, with decision algorithms tak-
ing into account of the genetic status of the patient.
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INTRODUCTION
Congenital hyperinsulinism (CHI) is the most 
common cause of nonketotic persistent severe 
hypoglycaemia in neonates, and is caused by an 
inappropriate insulin secretion from pancreatic 
ß cells. The estimated incidence of CHI is 1 in 
50,000 live births (1). A number of different ge-
netic causes has been associated with CHI. KATP 
channel subunits (ABCC8, KCNJ11) alterations 
are considered to be channelopathies, while 
metabolopathies are enzyme defects, tran-
scription factor defects or metabolic defects 
(GLUD1, SLC16A1, HNF4A, GCK, HNF1A, HADH, 
UCP2) (2).
CHI shows considerable genetic heterogeneity, 
it can be inherited in a recessive or dominant 
manner (3). Of the several genes implicated, 
the most common ones are ABCC8 (ATP bind-
ing cassette subfamily C member 8) and KCNJ11 
(potassium voltage-gated channel subfamily J 
member 11) being responsible for 40-50% of 
the cases. ATP sensitive K+ (KATP) channels are 
composed of eight subunits from two differ-
ent gene products, ABCC8 encoding SUR1 and 
KCNJ11 encoding Kir6.2 subunit (2). The KATP 
channel is a key component in the regulation of 
insulin secretion in response to elevating glu-
cose level. The channels close as a consequence 
of glucose metabolism (increased ATP level) 
leading to membrane depolarization which ulti-
mately results in the opening of a voltage-gated 
Ca2+ channel. The rise of the intracellular Ca2+ 
concentration stimulates exocytosis of insulin-
containing granules from the pancreatic ß cell 
(Figure 1). The KATP channel is a Janus-faced pro-
tein as gain-of-function mutations will lead to 
neonatal or maturity-onset diabetes while loss-
of-function mutations will cause CHI (4).
Histologically 2 different types of congenital hy-
perinsulinism can be distinguished. In diffuse 
forms all ß cells are affected, which is a result 
of an autosomal recessive CHI. In focal forms a 
localized hyperplasia is present in the otherwise 
normal pancreatic tissue. These focal lesions 
might be the results of two different events. 
One possible event is a paternally inherited mu-
tation in the ABCC8 or KCNJ11 gene that would 
remain silent, but if there is an acquired somatic 
deletion of the maternal allele, focal CHI will de-
velop because of the loss of heterozygosity. The 
ABCC8 and KCNJ11 containing chromosome 
region also contains several imprinted genes, 
which are responsible for cell replication. The 
paternally expressed genes are involved in cell 
replication, proliferation. Normally they are 
compensated by the maternally expressed gene 
products, but in case of maternal allele loss, ß 
cell hyperplasia will develop (8). 
Diffuse CHI is suspected when the detected al-
terations are homozygous, compound heterozy-
gous or in the case when only maternal hetero-
zygous mutation is found. 
Focal CHI is most commonly associated with 
paternal heterozygosity, but focal CHI has also 
been reported with mutations arising either de 
novo or of unknown parental origin. Although 
paternal heterozygosity has a higher probabil-
ity for focal CHI, additional investigation such 
as 18-fluoro-dopa PET-CT scanning is necessary 
to localize the lesion in focal CHI (Figure 2) (9). 
According to some reports a proportion with pa-
ternal heterozygous mutations might have dif-
fuse CHI which could be explained by dominant 
inheritance or inability to identify a maternal 
mutation in a recessively-inherited disease (2).
Rapid, high-throughput techniques for analysis 
of candidate genes have helped the care of pa-
tients with CHI. Genotyping guides further in-
vestigation of the patient and, because of the 
strong genotype-phenotype correlation, also 
the therapy (10,11). 
The main goal of CHI treatment is to prevent 
brain damage. The nutritional approach in-
cludes glucose infusion and enteral feeding. 
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Medical treatment includes administration of 
diazoxide, octreotide, nifedipine and glucagon. 
Diazoxide acts on the SUR1 subunit of the KATP 
channel. It keeps the channel open, halting in-
sulin secretion. Octreotide is a somatostatin an-
alogue that inhibits insulin secretion. Glucagon 
stimulates glycogenolysis and gluconeogenesis. 
Growing evidence of published cases suggest a 
novel treatment option, sirolimus therapy (12). 
When CHI patient fail to respond to medical 
treatment, surgery should be considered. For 
patients diagnosed with focal form, surgical 
resection of the lesion is the appropriate cure. 
In case of diffuse CHI subtotal pancreatectomy 
may be necessary in severe, medically unre-
sponsive cases (1). 
CASE REPORT
A term male infant was born after uneventful 
pregnancy. His birth weight was 4050 g (95-97 
percentile), Apgar scores at birth were 9 at 1 min 
and 10 at 5 min. The infant did not have any 
dysmorphic features or congenital anomalies. 
The mother was primipara and had no diabetes 
during pregnancy. Due to being large for gesta-
tional age blood glucose monitoring begun, and 
hypoglycaemia was detected at one hour of life. 
Figure 1 Mechanism of  the KATP channel regulated insulin secretion  
in pancreatic β-cell. Model of  the KATP channel protein subunits
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Table 1 Glucose, insulin and C-peptide levels during treatment
Upon  
admission
Day 1 Day 2 Reference range 
Blood glucose (mmol/L) 1.6 2.1 5.6 3.6-6.0
Insulin (mU/L) 16.65 4.46 N.D. 2.6-24 (in 
normoglycaemia)
C-peptide  (ng/mL) 2.43 0.76 N.D.
0.48-5 (in 
normoglycaemia)
Therapy glucose infusion diazoxide octreotide -
N.D.: not determined
Figure 2 Clinical diagnostic algorithm for management  
of  congenital hyperinsulinism integrating molecular genetic testing
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He was treated with i.v. glucose infusion and hy-
drocortisone. Adrenal insufficiency was exclud-
ed (cortisol level: 398 nmol/L, reference range: 
140-690 nmol/L). After the sixth day of life the 
blood glucose normalized, the infant did not re-
quire any medication. A diagnosis of transient 
hypoglycaemia was made. At the age of two 
months, he was admitted to hospital because 
of frequent myoclonic movements of the lower 
and later the upper limbs, sweat and pallor was 
observed with episodes of hypoglycaemia (glu-
cose: 1.1-1.9 mmol/L). In time of hypoglycae-
mia (glucose: 1.6 mmol/L) the insulin level was 
16.65 mU/L, and C-peptide level was 2.43 ng/mL. 
Normoglycaemia could only be maintained by 
continuous i.v. glucose load up to 20mg/kg/min. 
Insulin and C-peptide levels were elevated dur-
ing hypoglycaemia.
Oral diazoxide was administered because of the 
hyperinsulinism at 13 mg/kg/day in divided dos-
es. He had poor response to diazoxide, the glu-
cose infusion was further administered. With this 
therapy the blood glucose could be maintaned at 
2.1-2.3 mmol/l. Insulin was 4.5 mU/L, C-peptide 
was 0.76 ng/mL (Table 1). Genetic testing was ini-
tiated. After starting octreotide therapy his blood 
glucose begun to improve. Subcucatenously in-
troduced octreotide was successfully replaced 
by lancreotide every four weeks. 
Figure 3 Genetic analysis revealed a heterozygous c.4415-13G>A mutation  
of  the ABCC8 gene
Part A: Next-generation sequencing result  
Left Y axis shows the percentage of the mutant allele 
Right Y axis and the blue line show the coverage 
Region of the ABCC8 gene containing the mutation site is shown
Part B: Sanger sequencing electropherogram
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Genomic DNA was extracted from peripheral 
blood leukocytes. Next-generation panel gene 
sequencing was performed on a Roche GS Junior 
DNA sequencer using a Multiplicom MODY 
MASTR Kit which contains the following genes: 
ABCC8, GCK, HNF1A, HNF4A, HNF1B, INS and 
KCNJ11. The detected mutation was confirmed 
by Sanger sequencing.
We detected the c.4415-13G>A heterozygous 
mutation in the ABCC8 gene (Figure 3). Targeted 
genetic testing of the parents proved the de 
novo origin of the mutation. The c.4415-13G>A 
mutation has been previously described, and 
was associated with octreotide responsive, focal 
histological forms (4). Although there is no func-
tional study analyzing the consequence of the 
mutation, the c.4415-13G>A has been shown to 
be present in many CHI patients (5,6,7).
The infant received octreotide treatment and 
could be prepared for 18-fluoro-dopa PET-CT 
examination.
DISCUSSION
Early diagnosis and treatment is crucial for the 
appropriate management of CHI (1). The prima-
ry goal of treatment is to maintain normoglycae-
mia in order to prevent neurological damage. 
Rapid gene mutation analysis with short turn-
around time is a key part of the clinical man-
agement strategy, as it is shown in the decision 
algorithm (Figure 2). Importantly, the finding of 
a paternal heterozygous mutation or a de novo 
mutation is a key step before 18-fluoro-dopa 
PET-CT scanning and the subsequent possible 
finding of a solitary focal lesion in the pancre-
as that can be cured by lesionectomy (8,9,10). 
Genotype-phenotype correlations is also hel-
pful in the management of the patient (3,11). 
The treatment algorithm recommends the KATP 
agonist, diazoxide as first line therapy. Our pa-
tient was also octreotide responsive, similarly 
to the patient in the first literature report (4).
TAKE-HOME MESSAGES/LEARNING POINTS
1. CHI is a cause of severe hypoglycaemia in 
neonates. 
2. The main pathophysiological characteristic 
of CHI is that insulin secretion is indepen-
dent from the glucose concentration, show-
ing elevated insulin and C-peptide levels 
even in the presence of hypoglycaemia.
3. Loss of function mutations in the ABCC8 or 
in the KCNJ11 gene can lead to CHI.
4. Rapid genetic testing in patients with CHI is 
crucial and guides further investigations.
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